Risky Business...

Co-Moderator(s)

• 

  Alys Havard, PhD (she/her/hers)

  Senior Research Fellow
  National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia, Australia
• 

  Leyla Sahin, MD (she/her/hers)

  Deputy Director for Safety
  Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, USA
  Silver Spring, United States

Presentations:

• 1:00 PM – 1:15 PM ADT

  Benzodiazepine use early in pregnancy and risk of congenital malformations
  

  Presenting Author: Ayesha C. Sujan, PhD (she/her/hers) – Stanford University
• 1:15 PM – 1:30 PM ADT

  Risk of preterm birth associated with ADHD medication use in pregnancy
  

  Presenting Author: Jacqueline M. Cohen, PhD (she/her/hers) – Department of Chronic Diseases & Centre for Fertility and Health, Norwegian Institute of Public Health
• 1:30 PM – 1:45 PM ADT

  Prenatal exposure to selective serotonin reuptake inhibitors and risk of Disorders of Gut-Brain Interaction in the offspring
  

  Presenting Author: Helene Kildegaard, MD – Clinical Pharmacology, Pharmacy and Environmental Medicine, Dept. of Puiblic Health, University of Southern Denmark
• 1:45 PM – 2:00 PM ADT

  Antiseizure Medication During Pregnancy and Offspring Neurodevelopmental Outcomes: A Study of Two Cohorts from the UK and Sweden
  

  Presenting Author: Viktor H. Ahlqvist, MMsc – Karolinska Institutet
• 2:00 PM – 2:15 PM ADT

  Comparing Long-term Neurodevelopmental Outcomes in Children with Prenatal Exposure to Buprenorphine and Methadone: A Population-based Study
  

  Presenting Author: Mennatullah Hasan, PharmD – University of Rhode Island
• 2:15 PM – 2:30 PM ADT

  Fetal and Early Life Exposure to Antibiotics and the Risk of Neurodevelopmental Disorders: A Nationwide Population-Based Cohort Study with Sibling Analysis
  

  Presenting Author: Ahhyung Choi, PharmD – School of Pharmacy, Sungkyunkwan University